Upadacitinib in a 15 mg dose could achieve robust efficacy in PsA with limited adverse eventsSeptember 26, 2021Psoriasis
Rates of relevant counseling/education lower at dermatology vs. primary care PsA outpatient visitsSeptember 26, 2021Psoriasis
Affected body surface area predicts risk of PsA in patients with psoriasisSeptember 26, 2021Psoriasis
Risk of developing PsA significantly lower in psoriasis patients treated with biologicsSeptember 26, 2021Psoriasis
Dermatology NewsEuropean agency recommends two new adalimumab biosimilarsSeptember 20, 2021Psoriatic ArthritisPediatricsPsoriasis
Secukinumab therapy against plaque psoriasis yields high patient satisfactionSeptember 18, 2021Psoriasis
Abdominal subcutaneous adipose tissue elicits sex-specific effects on coronary atherosclerosis in psoriasisSeptember 18, 2021Psoriasis
Clobetasol propionate 0.025% is a safe treatment option for moderate-to-severe psoriasisSeptember 18, 2021Psoriasis
Impact of psoriasis on clinical outcomes in patients with pulmonary embolismSeptember 18, 2021Psoriasis
Calcipotriol-betamethasone more effective than calcipotriol alone in treating plaque psoriasisSeptember 18, 2021Psoriasis
Methotrexate or retinoids: Which one poses lower cardiovascular risks in psoriasis?September 18, 2021Psoriasis
